A packaging change should trigger a container closure integrity testing (CCIT) reassessment when it could affect the package's ability to maintain its required barrier throughout storage, transportation and use. Changes to container materials, stoppers, seals, caps, suppliers, manufacturing processes or sealing parameters may alter package performance even when the new components look identical. The right response is a documented, risk-based assessment—not automatically repeating every original test or assuming that a previously validated method remains suitable without review. Pharmaceutical quality teams should evaluate the change, identify affected failure modes, define the required evidence and approve implementation through the established change-control process.

 

Why Can a Packaging Change Affect Container Closure Integrity?

Container closure integrity depends on the complete packaging system, including the container, closure components, interfaces and assembly process. A change to one part can affect the performance of the system as a whole.

For pharmaceutical manufacturers, a packaging change may be introduced to improve supply availability, reduce cost, qualify a new supplier, modify production equipment or support a new product configuration. Although the change may appear minor, its impact on the package barrier may not be obvious from a visual inspection.

For example, two stoppers may have similar dimensions but differ in material properties. A new container supplier may provide components that meet the drawing but behave differently during sealing. A change in capping settings may alter how a closure is applied.

These changes do not automatically mean that package integrity has been compromised. They do mean that the manufacturer should determine whether existing evidence remains applicable.

Zholion provides CCIT testing services covering package development, component compatibility, manufacturing processes and stability studies. These capabilities are relevant when a change requires additional package integrity evidence.

 

Which Packaging Changes Should Trigger a CCIT Review?

The first step is to identify what has changed and how that change could affect the package's integrity.

Change category	Potential impact	Questions for the quality team
Container material	Different mechanical or barrier properties	Could the new material affect package performance or method suitability?
Stopper or seal material	Different compression, fit or contact behavior	Does the closure still function as intended with the container?
Closure dimensions or design	Changes to the sealing interface	Are the existing assembly settings and test method still appropriate?
Supplier change	Variation in component characteristics	Has the new source been qualified against the relevant requirements?
Container or closure manufacturing process	Differences in dimensions or surface characteristics	Could the process change introduce new failure modes?
Capping or sealing parameters	Different closure application conditions	Does the revised process maintain the required integrity?
Equipment, fixture or tooling	Different assembly or test conditions	Does the change affect the package or the measurement system?
Packaging format or size	Different geometry, headspace or stress distribution	Can the existing test method and fixture be applied reliably?

This table is a screening tool, not a universal rule that every listed change requires the same testing. The extent of reassessment should be justified by the change's potential impact, the available evidence and the product's risk profile.

 

How Should a Pharmaceutical Team Assess the Impact of a Change?

A structured assessment helps teams avoid two opposite problems: conducting unnecessary tests for a demonstrably low-risk change, or approving a meaningful packaging change without enough evidence.

Step 1: Describe the Change Precisely

Record the original configuration and the proposed configuration. Identify the affected component, supplier, material, dimensions, manufacturing process or equipment parameter.

The change description should explain why the change is needed and whether it affects one product, several products or multiple packaging configurations.

Avoid broad descriptions such as “supplier improvement” or “minor component update.” Those phrases do not establish what has changed or whether the existing evidence remains applicable.

 

Step 2: Identify Potential Failure Modes

Consider how the change could affect the package's ability to prevent leakage or maintain the required barrier.

Depending on the package, relevant risks may include:

• Loss of fit between the container and closure.

• Changes in seal formation or compression.

• Cracks, deformation or damage introduced during assembly.

• Increased sensitivity to temperature or mechanical stress.

• Changes to the package's headspace or internal pressure behavior.

• New limitations in the selected leak-test method.

Not every risk applies to every package. The assessment should reflect the actual container closure system rather than use a generic checklist without technical review.

 

Step 3: Review Existing Evidence

Before commissioning new tests, determine what the existing development and validation records already demonstrate.

Relevant evidence may include component specifications, dimensional data, supplier qualification records, assembly-process studies, package integrity validation, stability results and previous change assessments.

The key question is whether that evidence adequately represents the proposed configuration.

For example, existing data may remain relevant when an administrative detail changes without affecting the component or process. A change to a sealing interface, however, may require new compatibility or integrity evidence.

 

Step 4: Determine Whether the Existing CCIT Method Remains Suitable

A packaging change can affect the package itself, but it may also affect the measurement behavior of the chosen test method.

A method previously established for one container configuration should not automatically be assumed suitable for a materially different configuration. Changes in package dimensions, material properties, headspace or flexibility may influence test response.

Zholion's CCIT test methods include vacuum decay, while its broader leak detection equipment range includes pressure decay, helium leak detection and high-voltage leak detection. The appropriate method depends on the package, product state, expected defect and required detection capability.

Where the change affects method suitability, the team should determine whether feasibility testing, method verification or a more extensive validation activity is necessary.

 

Step 5: Define the Required Verification

The assessment should lead to a clear testing plan. Depending on the risk, this could involve document review alone, component compatibility studies, additional CCIT testing, process verification, stability-related assessments or a combination of activities.

The plan should specify:

• Which package configuration will be evaluated.

• Which risks the study is intended to address.

• Which test method and operating conditions will be used.

• What samples and controls are required.

• What acceptance criteria apply.

• How the results will be documented and approved.

Do not select a test solely because it was used for the original package. The test must be suitable for the specific question raised by the change.

 

When Is a Full Revalidation Necessary?

There is no single answer that applies to every packaging change. The decision depends on the nature of the change, the existing validation evidence, the product's requirements and the applicable quality system.

A limited assessment may be defensible when the change is well understood, relevant characteristics remain unchanged and documented evidence supports the conclusion.

A broader study may be needed when a change affects a critical sealing interface, introduces a different material, modifies the assembly process, changes the package geometry or creates uncertainty about the original test method's detection capability.

The following decision framework can help structure the discussion.

Situation	Potential response	Evidence to consider
Administrative change with no technical impact	Documented impact assessment	Approved specifications and change records
New supplier with equivalent component specification	Supplier qualification and targeted verification	Dimensional, material and performance comparison
Changed closure or sealing interface	Additional package integrity evaluation	Component compatibility, assembly and CCIT results
Changed process parameters	Process verification and integrity assessment	Process data, representative samples and test results
Changed package geometry or material properties	Review of method suitability and possible method reassessment	Feasibility studies, test sensitivity and package-specific evidence
Unclear or potentially significant impact	Expanded risk assessment and study plan	Technical investigation and additional verification

This framework does not replace product-specific regulatory or quality requirements. The responsible quality unit should approve the final scope.

 

How Can CCIT Help Verify a Packaging Change?

CCIT provides evidence about the integrity of the tested package under defined conditions. It can be used alongside component, process and stability data to evaluate whether a revised packaging system continues to meet its intended requirements.

Vacuum Decay Testing

Vacuum decay evaluates pressure changes in an evacuated test chamber containing the package. It is a non-destructive method for suitable rigid and selected flexible packaging configurations.

It may be considered when evaluating changes to vials, bottles and other compatible packages, provided the method and test fixture are suitable for the new configuration.

Pressure Decay Testing

Pressure decay evaluates pressure loss under defined positive-pressure conditions. It may be useful for appropriate packaging systems, including certain flexible packages that deform significantly under vacuum.

The selection must be based on the package's characteristics and demonstrated method suitability.

Helium Leak Testing

Helium leak testing uses helium as a tracer gas and can support quantitative investigation of very small leaks. It may be considered when the study requires high-sensitivity leak-rate evaluation and the package configuration is compatible with the method.

Component Compatibility and Process Verification

CCIT should not be treated as the only source of evidence. Component dimensions, material compatibility, closure application, process settings and stability-related behavior may also need evaluation.

A package can pass a particular leak test under the evaluated conditions without proving every aspect of its long-term performance. The study should therefore address the actual risks introduced by the change.

 

What Should the Change-Control Record Contain?

A well-organized record helps explain why the change was approved and provides traceability for future investigations or inspections.

At minimum, document:

1. The original and proposed packaging configurations.

2. The reason for the change and the products affected.

3. The risk assessment and potential failure modes.

4. The existing evidence reviewed.

5. The rationale for selecting or retaining the CCIT method.

6. The testing plan, acceptance criteria and results.

7. Any deviations, unexpected findings or corrective actions.

8. The quality-unit decision and implementation approval.

9. Any updates required for specifications, procedures, supplier records or training.

If the change affects multiple products, explain whether one study can reasonably represent all affected configurations. A common material or component does not automatically mean that every package has identical risk.

 

Common Mistakes in Packaging Change Control

Assuming identical dimensions mean identical performance. Material characteristics, tolerances and assembly behavior can differ even when nominal dimensions match.

Relying only on supplier documentation. Supplier records are important, but the pharmaceutical manufacturer must determine whether the evidence is sufficient for its own product and process.

Repeating the original test without reviewing method suitability. The method may need adjustment or reassessment if the package configuration changes.

Treating a passing CCIT result as complete proof of equivalence. Package integrity is one part of a broader assessment that may include component compatibility, process capability and stability.

Failing to document why additional testing was not needed. A justified decision not to repeat a test should still be supported by a documented assessment.

Implementing the change before the required review is complete. The change-control process should define when the new configuration can be introduced.

 

Frequently Asked Questions

Does every packaging material change require CCIT revalidation?

No. The required response depends on whether the change could affect package integrity or the validity of existing evidence. The decision should be documented and justified.

Does changing a stopper supplier require additional leak testing?

It may. The team should compare the relevant component characteristics, assess compatibility with the container and assembly process, and determine whether additional verification is needed.

Can the original CCIT method be used after a packaging change?

Possibly, but suitability should be assessed. Changes to package material, dimensions, headspace or flexibility may affect the method's response or the required test fixture.

Is CCIT sufficient to approve a packaging change?

Not necessarily. CCIT may be part of the evidence, alongside component qualification, process verification, compatibility studies and stability-related assessments as appropriate.

Who should approve the final decision?

The responsible quality unit should approve the change according to the organization's change-control procedure and applicable requirements, with input from packaging engineering, manufacturing, validation and regulatory teams where relevant.

 

Discuss Packaging Change Assessment with Zholion

Packaging changes can affect container closure integrity in ways that are not apparent from visual inspection or component specifications alone. A documented risk assessment helps determine which evidence is needed before the revised configuration enters routine production.

Zholion supports pharmaceutical and medical device manufacturers with CCIT equipment, test-method selection, package-specific fixtures and testing services. Share the original and revised package configurations, the nature of the change, the existing test method and the question that needs to be resolved.

Contact Zholion

Email: marketing@zholion.com

Website: https://www.zholionccit.com/